{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:Q9NYD6",
      "entity_text" : "HOXC10",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ01860",
      "entity_text" : "bevacizumab",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Strikingly, treatment with bevacizumab, a monoclonal antibody against VEGFA, significantly inhibited the growth of HOXC10 overexpressing tumors and efficiently impaired angiogenesis.",
  "reading_complete" : "2020-08-03T16:54:57Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T16:53:21Z",
  "trigger" : "inhibited",
  "evidence" : [ "bevacizumab, a monoclonal antibody against VEGFA, significantly inhibited the growth of HOXC10" ],
  "pmc_id" : "6217061",
  "score" : 0
}